A Deadline is coming up on September 10, 2018 in the lawsuit for investors in MEDNAX, Inc. (NYSE: MD) and NYSE: MD stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 09/10/2018 -- A deadline is coming up on September 10, 2018 in the lawsuit filed for investors in NYSE: MD shares over alleged securities laws violations by MEDNAX, Inc.
Investors who purchased shares of MEDNAX, Inc. (NYSE: MD) have certain options and there are strict and short deadlines running. Deadline: September 10, 2018. NYSE: MD stockholders should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The plaintiff claims that between February 4, 2016 to July 27, 2017, Mednax's business model depended upon growth from the acquisition of new practice groups, primarily in anesthesiology, and that in truth, Mednax's business model is not sustainable and its growth was based upon suppressing physician compensation and enforcing non-compete agreements to deter physician defections.
Those who purchased shares of MEDNAX, Inc. (NYSE: MD) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels